A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Yu, Songfeng; Guo, Hua; Li, Zhuang; Yu, Jun; Yan, Sheng; Zhang, Min; Wang, Weilin; Zheng, Shusen

doi:10.1186/1477-7819-11-176

Cited by 14 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On imaging it shows characteristic arterial phase enhancement with washout in venous phase and delayed capsular enhancement. De novo HCC is rarely encountered and chronic HCV and HBV infection remains a high risk factor for the development of HCC (10).…”

Section: Discussionmentioning

confidence: 99%

Imaging of Kaposi sarcoma in a transplanted liver: A rare case report

Gupta

Ghuman

Buxi

et al. 2015

The Egyptian Journal of Radiology and Nuclear Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Imaging of Kaposi sarcoma in a transplanted liver: A rare case report

Gupta

Ghuman

Buxi

et al. 2015

The Egyptian Journal of Radiology and Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…Although current treatment guidelines for De-novo HCC after LT have not been well established, it was suggested that these cases be approached according to the current guidelines for primary and recurrent HCC[ 17 ]. The strategies that have been used in the reported cases to date are: re-transplantation ( n = 6)[ 4 , 6 - 9 , 14 ], trans-arterial chemoembolization (TACE) ( n = 4)[ 11 , 13 - 15 ], hepatic resection ( n = 3)[ 7 , 12 ], radiofrequecy ablation (RFA) ( n = 3)[ 10 , 11 , 14 ], medical therapy with Sorafenib ( n = 2)[ 13 , 14 ] and PMWA in our case. Two of the reported cases used more than one procedure[ 7 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

De-novohepatocellular carcinoma after pediatric living donor liver transplantation

Torres-Landa

Muñoz-Abraham

Fortune

et al. 2017

WJH

View full text Add to dashboard Cite

De-novo malignancies carry an incidence ranging between 3%-26% after transplant and account for the second highest cause of post-transplant mortality behind cardiovascular disease. While the majority of de-novo malignancies after transplant usually consist of skin cancers, there has been an increasing rate of solid tumor cancers over the last 15 years. Although, recurrence of hepatocellular carcinoma (HCC) is well understood among patients transplanted for HCC, there are increasing reports of de-novo HCC in those transplanted for a non-HCC indication. The proposed pathophysiology for these cases has been mainly connected to the presence of advanced graft fibrosis or cirrhosis and always associated with the presence of hepatitis B or C virus. We report the first known case of de-novo HCC in a recipient, 14 years after a pediatric living related donor liver transplantation for end-stage liver disease due to biliary atresia without the presence of hepatitis B or C virus before and after transplant. We present this case report to increase the awareness of this phenomenon and address on the utility for screening and surveillance of hepatocellular carcinoma among these individuals. One recommendation is to use similar guidelines for screening, diagnosis, and treatment for HCC as those used for primary HCC in the pre-transplant patient, focusing on those recipients who have advanced fibrosis in the allograft, regardless of etiology.

show abstract

“…In particular, few cases of de novo HCC in LDLT have been reported. 6,7 Hence, the characteristics, probability of, and risk factors for de novo HCC remain poorly understood. In this study, we defined the donor origin of graft HCC using microsatellite analysis and elucidated the characteristics of de novo HCC from a database containing 2779 LDLT adult cases from nine major LT institutes in Japan.…”

Section: Introductionmentioning

confidence: 99%

“…Published studies on the development of de novo HCC in the graft post‐transplant are restricted by the limited number of case reports. In particular, few cases of de novo HCC in LDLT have been reported 6,7 . Hence, the characteristics, probability of, and risk factors for de novo HCC remain poorly understood.…”

Section: Introductionmentioning

confidence: 99%

De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience

Goto

Kosai‐Fujimoto

Yagi

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

Direct-acting antivirals for hepatitis C virus have reduced the decompensation risk. Immunosuppressants for transplantation raise the risk of occurrence of de novo malignancies. We assessed the probabilities of and risk factors for de novo hepatocellular carcinoma (HCC) development post-living donor liver transplantation (LDLT). Methods: We retrospectively evaluated the data of developed HCC in a graft including metastatic HCC post-LDLT from 2779 adult cases collected from nine major liver transplantation centers in Japan. Results: Of 2779 LDLT adult recipients, 34 (1.2%) developed HCCs in their grafts. Of 34, five HCCs appeared to be de novo because of a longer period to tumor detection (9.7 [6.4-15.4] years) and no HCC within the native liver of the two recipients. The donor origin of three of five de novo HCCs was confirmed using microsatellite analysis in resected tissue. Primary disease of all five was hepatitis C virus-related cirrhosis, of which two were treated with direct-acting antivirals. Four of five developed HCC de novo in the hepatitis B core antibody-positive grafts. De novo HCCs had favorable prognosis; four of five were cured with complete remission. However, recurrent HCC (n=29) in the graft had a poorer outcome, especially in patients with neutrophil to lymphocyte ratio scores above 4 (median survival time, 262 [19-463] days). Conclusion: Analysis of the database from major liver transplantation institutes in Japan revealed that de novo HCCs determined by microsatellite analysis were rarely detected, but the majority were successfully treated. LDLT recipients with higher

show abstract

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Cited by 14 publications

References 23 publications

Imaging of Kaposi sarcoma in a transplanted liver: A rare case report

Imaging of Kaposi sarcoma in a transplanted liver: A rare case report

De-novohepatocellular carcinoma after pediatric living donor liver transplantation

De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience

Contact Info

Product

Resources

About